Skip to main content

Hyperchloremia, a necessary evil in neurocritical care

The Original Article was published on 27 January 2023

Dear Editor:

We read with interest the recent article by Huet et al. A post hoc study from the COBI trial compared the impact of continuous hypertonic (NaCl 20%) saline solution on renal outcomes after traumatic brain injury (TBI), specifically, if a high dose of chloride delivered by hypertonic saline solution was associated with an increased incidence of acute kidney injury. In their conclusion, they question the detrimental effect of chloride on kidney function [1]. However, it is necessary to mention some relevant aspects of acute kidney injury in neurocritical care patients.

  1. 1.

    Hyperchloremia has been hypothesized to cause renal hypoperfusion and AKI by its renal vascular smooth muscle constrictor effect and other mechanisms [1]. Therefore, there is a pathophysiological rationale to support its association with AKI.

    The randomized controlled trials SMART and SALT-ED support this relationship. The participants in the SMART trial who received balanced solutions had 10% lower odds of major adverse kidney events within 30 days. Similar results for SALT-ED, with 18% lower odds of MAKE-30, compared with normal saline. Additionally, those who presented to the emergency department with renal dysfunction or hyperchloremia received the largest benefit from balanced solutions for avoiding AKI. However, these results are limited to a primarily non-neurocritical population. It is important to note that in neurocritical patients the administration of saline solution and not a balanced solution is indicated due to the risk of cerebral edema. However, it is necessary to be attentive to the effects of severe hyperchloremia that neurocritical patients can develop. Nevertheless, Riha et al. [2] demonstrated significantly higher rates of in-hospital mortality in patients with intracerebral hemorrhage who developed moderate hyperchloremia during hypertonic 3% solution treatment. Additionally, the ACETatE trial, a pilot study, decreased the chloride load and the incidence of AKI (11.8% vs 53.3%, p = 0.01) using a hypertonic solution with a lower chloride content of 16.4% sodium chloride/sodium acetate vs 23.4% sodium chloride for the treatment of cerebral edema [3]. This study supports the hypothesis that chloride may be a potentiator of AKI in this population.

  2. 2.

    The actual comparison was patients with hyperchloremia vs patients with greater hyperchloremia (e.g., 114.5 ± 6.4 mmol/L vs 122.8 ± 8.1 mmol/L at day 2), making it difficult to find a difference in this scenario.

  3. 3.

    More than 50% of the patients received hypertonic therapy before inclusion, and even both groups received more than 50%, of mannitol, another controversial solution.

  4. 4.

    The definition of AKI only included patients with KDIGO 2 or 3. It is important to mention that the reports of AKI in neurocritical patients show a high incidence of KDIGO 1, which is associated with worse outcomes and worse functional recovery [4]. Failure to report this group may be a factor for not finding differences. When trying to use more severe stages, as in this case, it is possible to classify some AKI cases as negative endpoints because it only achieved KDIGO 1, being really a true AKI case and not just purely functional and transitory. Therefore, defining the AKI outcome in neurocritical patients must be carefully evaluated.

  5. 5.

    Augmented renal clearance is likely to complicate the care of TBI patients with normal plasma creatinine concentrations, limiting our AKI diagnosis by usual markers. Using biomarkers such as NGAL increases our diagnosis of acute tubular injury in patients with normal creatinine after a TBI [5].

Therefore, like the primary study, we believe that the COBI post hoc study should not change our clinical practice by requiring hypertonic solutions in the context of intracranial hypertension. However, we must not think that the increases in chloride will not have repercussions at the kidney level.

Availability of data and materials

Not applicable.

References

  1. Huet O, Chapalain X, Vermeersch V, et al. Impact of continuous hypertonic (NaCl 20%) saline solution on renal outcomes after traumatic brain injury (TBI): a post hoc analysis of the COBI trial. Crit Care. 2023;27(1):42.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Riha HM, Erdman MJ, Vandigo JE, et al. Impact of moderate hyperchloremia on clinical outcomes in intracerebral hemorrhage patients treated with continuous infusion hypertonic saline: a pilot study. Crit Care Med. 2017;9:e947–53.

    Article  Google Scholar 

  3. Sadan O, Singbartl K, Kraft J, et al. Low-chloride-versus high-chloride-containing hypertonic solution for the treatment of subarachnoid hemorrhage-related complications: the ACETatE (a low chloride hypertonic solution for brain Edema) randomized trial. J Intensive Care. 2020;4(8):32.

    Article  Google Scholar 

  4. Fandler-Hofler S, Odler B, Kneihsl M, et al. Acute and chronic kidney dysfunction and outcome after stroke thrombectomy. Transl Stroke Res. 2021;12(5):791–8.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Civiletti F, Assenzio B, Mazzeo AT, et al. Acute tubular injury is associated with severe traumatic brain injury: in vitro study on human tubular epithelial cells. Sci Rep. 2019;9(1):6090.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

None.

Funding

There was no funding for the study.

Author information

Authors and Affiliations

Authors

Contributions

GRG designed the work, GRG collected and analyzed the data, GRG, MM, and TR drafted the work or substantively revised it, and all authors read and approved the final manuscript.

Corresponding author

Correspondence to Gonzalo Ramírez-Guerrero.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors report no conflicts of interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article. The authors alone are responsible for the content and writing of this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ramírez-Guerrero, G., Marcello, M. & Reis, T. Hyperchloremia, a necessary evil in neurocritical care. Crit Care 27, 353 (2023). https://doi.org/10.1186/s13054-023-04639-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13054-023-04639-8